FDA Accepts Supplemental NDA for Oxycodone Hydrochloride by Vistapharm
The FDA has accepted a supplemental NDA for Oxycodone Hydrochloride submitted by Vistapharm.
Asset / Drug
Drug and asset intelligence for Vistapharm with 2 indexed intelligence signals across regulatory, clinical, competitive, and market developments.
No catalysts indexed for this entity yet.
No related entities indexed yet.
Newsletter
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.